The drugmaker’s revenue rose 5% when adjusted for currency changes, driven by growth in oncology sales.
A drug used to treat patients with life-threatening illnesses has received an important update after substantial community ...
Better-than-expected sales helped Biogen regain the support of investors, while AstraZeneca and GSK worked to convince Wall ...
United Kingdom-based biopharmaceutical giant AstraZeneca will add 10 to 15 new projects to the company's research and ...
AstraZeneca executives told Fierce they are “very confident” in the pharma’s in-house pipeline of antibody-drug conjugates ...
AstraZeneca delivered solid core EPS growth of 18% YoY, while revenue growth came in line with expectations for the full year ...
AstraZeneca Plc reported higher-than-expected profit, buoyed by blockbuster cancer medicines, as focus turns to the company’s ...
Daniel covers the intersection of the health industry and the federal government. He reports on corporate influence in government, the health consequences of federal policies, and the politics of ...
20d
AstraZeneca's trial flop raises a bigger question: Is its pipeline premium becoming more vulnerable?
For years, AstraZeneca has commanded one of the richest valuations among large European pharma companies on the assumption that it consistently delivers results.
Europe and US risk being outpaced on innovation, as happened in the car industry, warns Pascal Soriot ...
July 27 (Reuters) - AstraZeneca has been adjusting its pricing strategy for new drug launches in response to U.S. President ...
July 27 (Reuters) - AstraZeneca said on Monday its rare disease drug Ultomiris failed a late-stage trial in patients with a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results